Inspira Technologies Oxy B.H.N. LTD (IINNW) — SEC Filings

Overview

Inspira Technologies Oxy B.H.N. LTD (IINNW) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 6-K filed on Dec 31, 2025: Inspira Technologies Oxy B.H.N. Ltd. held its Annual and Extraordinary General Meeting of Shareholders on December 30, 2025. The meeting was initially adjourned due to a lack of quorum but was successfully convened later that day at 6:00 p.m. Israel time.

Sentiment Summary

Across 50 filings, the sentiment breakdown is: 18 bullish, 1 bearish, 30 neutral, 1 mixed. The dominant filing sentiment for Inspira Technologies Oxy B.H.N. LTD is neutral.

Filing Type Overview

Inspira Technologies Oxy B.H.N. LTD (IINNW) has filed 48 6-K, 1 20-F/A, 1 20-F with the SEC between Jan 2025 to Dec 2025.

Recent Filings (50)

• Inspira Technologies Holds Shareholder Meeting After Adjournment — 6-K · Dec 31, 2025 Risk: low
  Inspira Technologies Oxy B.H.N. Ltd. held its Annual and Extraordinary General Meeting of Shareholders on December 30, 2025. The meeting was initially adjourned
• Inspira Technologies Reaffirms $49.5M in Orders, Eyes 2026 Milestones — 6-K · Dec 23, 2025 Risk: medium
  On December 23, 2025, Inspira Technologies Oxy B.H.N. Ltd. issued a press release reaffirming $49.5 million in binding purchase orders. The company is aligning
• 6-K Filing — 6-K · Dec 15, 2025
• Inspira Technologies Secures Japanese Patent for ART System Cannula — 6-K · Dec 9, 2025 Risk: medium
  Inspira Technologies Oxy B.H.N. Ltd. announced on December 9, 2025, that it has been granted a patent in Japan for its INSPIRA™ ART System's Convertible Dual Lu
• Inspira Technologies Enhances Lab Capabilities for Diagnostics — 6-K · Dec 3, 2025 Risk: low
  On December 3, 2025, Inspira Technologies Oxy B.H.N. Ltd. announced a strategic advancement in its laboratory capabilities, aiming to accelerate the development
• 6-K Filing — 6-K · Nov 25, 2025
• 6-K Filing — 6-K · Nov 13, 2025
• Inspira Technologies Nears UAE Regulatory Clearance for ART100 — 6-K · Nov 6, 2025 Risk: medium
  On November 6, 2025, Inspira Technologies Oxy B.H.N. Ltd. announced it is nearing final regulatory clearance for its ART100 device in the United Arab Emirates.
• Inspira Technologies & Bites Forge AI Strategic Alliance — 6-K · Oct 22, 2025 Risk: low
  On October 22, 2025, Inspira Technologies Oxy B.H.N. Ltd. announced a strategic alliance with Bites to integrate AI into its global ecosystem. This partnership
• Inspira Technologies Appoints New VP Global Sales & Board Member — 6-K · Oct 21, 2025 Risk: medium
  On October 21, 2025, Inspira Technologies Oxy B.H.N. Ltd. announced the appointment of a former Johnson & Johnson Senior Business Manager as its new VP of Globa
• Inspira Technologies Reports H1 2025 Financials — 6-K · Oct 1, 2025 Risk: low
  Inspira Technologies Oxy B.H.N. Ltd. filed a Form 6-K on October 1, 2025, reporting its financial results for the first half of 2025. The filing includes a pres
• Inspira Technologies to Unveil HYLA Blood Sensor — 6-K · Sep 18, 2025 Risk: medium
  On September 18, 2025, Inspira Technologies Oxy B.H.N. Ltd. announced it will unveil its HYLA™ Real-Time Blood Sensor at the U.S. ELSO conference. The company c
• Inspira Technologies Ups Share Offering by $2.8M — 6-K · Sep 16, 2025 Risk: medium
  On September 16, 2025, Inspira Technologies Oxy B.H.N. Ltd. announced an increase in the maximum aggregate offering price of its ordinary shares under its Sales
• Inspira's HYLA Blood Sensor Hits 97.35% Accuracy — 6-K · Sep 11, 2025 Risk: medium
  On September 11, 2025, Inspira Technologies Oxy B.H.N. Ltd. announced that its HYLA™ Blood Sensor achieved 97.35% accuracy in recent tests. This significant mil
• Inspira ART100 System Used in Lung Transplants — 6-K · Sep 2, 2025 Risk: medium
  On September 2, 2025, Inspira Technologies Oxy B.H.N. Ltd. announced that a top U.S. Honor Roll Hospital has expanded its use of the Inspira ART100 System to in
• Inspira Technologies Secures US Patent for ART500 Tech — 6-K · Aug 22, 2025 Risk: medium
  On August 22, 2025, Inspira Technologies Oxy B.H.N. Ltd. announced it received U.S. Patent approval for its ART500 core technology. This patent is expected to p
• Inspira Technologies Lands $27M Government Order for ART100 — 6-K · Aug 19, 2025 Risk: medium
  Inspira Technologies Oxy B.H.N. Ltd. announced on August 19, 2025, that it has secured a binding purchase order from a government entity for its ART100 systems,
• Inspira Technologies Hires US Firm for Strategic Initiatives — 6-K · Jul 31, 2025 Risk: medium
  On July 31, 2025, Inspira Technologies Oxy B.H.N. Ltd. announced it has engaged a U.S.-based consulting firm to execute transformational initiatives. The press
• Inspira Technologies Regains Nasdaq Bid Price Compliance — 6-K · Jul 18, 2025 Risk: medium
  On July 18, 2025, Inspira Technologies Oxy B.H.N. Ltd. announced it has regained compliance with the Nasdaq minimum bid price requirement. This is a positive de
• Inspira Technologies Director Resigns — 6-K · Jul 17, 2025 Risk: low
  On July 16, 2025, Joe Hayon resigned from the Board of Directors of Inspira Technologies Oxy B.H.N. Ltd. His resignation was effective immediately and was not d
• Inspira Technologies Secures Government Deal for ART100 — 6-K · Jul 10, 2025 Risk: medium
  On July 10, 2025, Inspira Technologies Oxy B.H.N. Ltd. announced it has achieved all key objectives in government talks, paving the way for national adoption an
• Inspira in Gov Talks for ART100 Integration & Global Distribution — 6-K · Jul 7, 2025 Risk: medium
  On July 7, 2025, Inspira Technologies Oxy B.H.N. Ltd. announced it is in high-level government discussions to integrate its ART100 technology nationally and est
• Inspira Technologies Lands $22.5M Purchase Order — 6-K · Jul 2, 2025 Risk: medium
  On July 2, 2025, Inspira Technologies Oxy B.H.N. Ltd. announced it secured a $22.5 million purchase order, marking the commencement of its full revenue executio
• Inspira Technologies Ups Share Offering to $7.1M — 6-K · Jul 1, 2025 Risk: medium
  On July 1, 2025, Inspira Technologies Oxy B.H.N. Ltd. announced an increase in the maximum aggregate offering price of its ordinary shares under its Sales Agree
• Inspira Technologies Shareholders Approve Key Agenda Item — 6-K · Jun 23, 2025 Risk: low
  Inspira Technologies Oxy B.H.N. Ltd. held an Extraordinary General Meeting of Shareholders on June 20, 2025. A quorum was present, and shareholders approved the
• Inspira's ART100 Gains Traction in US Hospitals — 6-K · Jun 11, 2025 Risk: medium
  Inspira Technologies Oxy B.H.N. Ltd. announced on June 11, 2025, that its ART100 device is being used in Tier-1 U.S. hospitals, leading to significant clinical
• Inspira Technologies Scales ART100 Production, Eyes European Deal — 6-K · Jun 5, 2025 Risk: medium
  Inspira Technologies Oxy B.H.N. Ltd. announced on June 5, 2025, that it is scaling up production for its ART100 device. This move is happening concurrently with
• Inspira Technologies Schedules Shareholder Meeting for June 20 — 6-K · May 30, 2025 Risk: low
  Inspira Technologies Oxy B.H.N. Ltd. has filed a Form 6-K on May 30, 2025, announcing an Extraordinary General Meeting of Shareholders scheduled for June 20, 20
• Inspira Technologies Launches ART100 System Globally — 6-K · May 29, 2025 Risk: medium
  On May 29, 2025, Inspira Technologies Oxy B.H.N. Ltd. announced the global commercial rollout of its FDA-cleared ART100 system. This marks a significant step in
• Inspira Technologies Restructures Executive Team — 6-K · May 27, 2025 Risk: medium
  On May 27, 2025, Inspira Technologies Oxy B.H.N. Ltd. announced executive team realignments as part of corporate structuring initiatives. This announcement was
• Inspira Technologies Shareholders Approve All Meeting Agenda Items — 6-K · May 12, 2025 Risk: low
  On May 12, 2025, Inspira Technologies Oxy B.H.N. Ltd. held an Extraordinary General Meeting of Shareholders where all agenda items were approved by the required
• Inspira ART100 System Approved by Israel's Largest Healthcare Provider — 6-K · May 7, 2025 Risk: medium
  Inspira Technologies Oxy B.H.N. Ltd. announced on May 7, 2025, that its INSPIRA ART100 System has been approved by Clalit Health Services, Israel's largest heal
• Inspira Technologies VORTX™ Tech Hits 99%+ Gas Exchange Efficiency — 6-K · Apr 23, 2025 Risk: medium
  On April 23, 2025, Inspira Technologies Oxy B.H.N. Ltd. announced successful in-vivo animal testing for its VORTX™ technology, achieving over 99% gas exchange e
• Inspira Technologies Generates First Revenues from ART100 Systems — 6-K · Apr 15, 2025 Risk: medium
  On April 15, 2025, Inspira Technologies Oxy B.H.N. Ltd. announced it has generated its first revenues from the deployment of its INSPIRA ART100 systems. This ma
• Inspira Technologies Ups Share Offering to $1.9M — 6-K · Apr 10, 2025 Risk: low
  On April 10, 2025, Inspira Technologies Oxy B.H.N. Ltd. announced an increase in the maximum aggregate offering price of its ordinary shares under its Sales Agr
• Inspira Technologies ART100 Treats First Patient — 6-K · Apr 7, 2025 Risk: medium
  Inspira Technologies Oxy B.H.N. Ltd. announced on April 7, 2025, the successful treatment of its first patient using the INSPIRA ART100 device at Westchester Me
• Inspira Technologies Files 20-F/A Amendment — 20-F/A · Mar 28, 2025 Risk: medium
  Inspira Technologies OXY B.H.N. Ltd filed an amendment (20-F/A) to its annual report for the fiscal year ended December 31, 2024. The filing, dated March 28, 20
• Inspira Technologies Installs ART100 Systems in US Hospital — 6-K · Mar 25, 2025 Risk: medium
  On March 25, 2025, Inspira Technologies Oxy B.H.N. Ltd. announced the successful installation of its INSPIRA ART100 systems in a premier U.S. hospital. This mar
• Inspira Technologies Signs Sales Agreement for Share Offerings — 6-K · Mar 14, 2025 Risk: medium
  On March 14, 2025, Inspira Technologies Oxy B.H.N. Ltd. entered into a Sales Agreement with A.G.P./Alliance Global Partners. This agreement allows Inspira Techn
• Inspira Technologies CEO Update: Respiratory Care Milestones — 6-K · Mar 14, 2025 Risk: low
  On March 14, 2025, Inspira Technologies Oxy B.H.N. Ltd. issued a press release detailing significant milestones in their respiratory care advancements. The upda
• Inspira Technologies gets Nasdaq bid price warning — 6-K · Mar 13, 2025 Risk: medium
  Inspira Technologies Oxy B.H.N. Ltd. received a Nasdaq notification on March 13, 2025, stating that its stock has not met the minimum bid price requirement of $
• Inspira Technologies Files 2024 Financial Results — 6-K · Mar 11, 2025 Risk: low
  Inspira Technologies Oxy B.H.N. Ltd. filed a Form 6-K on March 11, 2025, to report its full-year 2024 financial results and provide business updates. The filing
• Inspira Technologies Files 2024 Annual Report — 20-F · Mar 10, 2025 Risk: medium
  Inspira Technologies OXY B.H.N. Ltd. filed its annual report on Form 20-F for the fiscal year ended December 31, 2024. The company, incorporated in Israel and o
• Inspira Technologies HYLA Blood Sensor Achieves 96% Accuracy in Study — 6-K · Mar 4, 2025 Risk: medium
  Inspira Technologies Oxy B.H.N. Ltd. announced on March 4, 2025, positive results from a clinical study of its HYLA Blood Sensor. The study demonstrated a 96% a
• Inspira Technologies Reports Over 95% Success in Infection Prevention — 6-K · Feb 11, 2025 Risk: medium
  On February 11, 2025, Inspira Technologies Oxy B.H.N. Ltd. announced positive results from its study on preventing bloodstream infections, achieving over 95% ef
• Inspira Technologies Addresses Trade Policy Impact — 6-K · Feb 10, 2025 Risk: medium
  Inspira Technologies Oxy B.H.N. Ltd. commented on its strategic position on February 10, 2025, in response to potential U.S. trade policy changes impacting Euro
• Inspira Technologies Enhances HYLA Blood Sensor with Oxygenation Indicator — 6-K · Feb 5, 2025 Risk: low
  On February 5, 2025, Inspira Technologies Oxy B.H.N. Ltd. announced the integration of a new oxygenation indicator into its AI-powered HYLA Blood Sensor. This d
• Inspira Technologies Enhances INSPIRA ART100 Device — 6-K · Jan 27, 2025 Risk: low
  On January 27, 2025, Inspira Technologies Oxy B.H.N. Ltd. announced advancements for its INSPIRA ART100 device. These new features aim to enhance user and syste
• Inspira Technologies Appoints New Chairman — 6-K · Jan 21, 2025 Risk: low
  Inspira Technologies Oxy B.H.N. Ltd. announced on January 19, 2025, that the board appointed Mr. Tal Parnes as the new chairman, effective February 1, 2025. Thi
• Inspira Tech Partners With Zriha Medical for New Production Line — 6-K · Jan 17, 2025 Risk: medium
  On January 17, 2025, Inspira Technologies Oxy B.H.N. Ltd. announced a collaboration with Zriha Medical to launch a new production line. This partnership aims to

Risk Profile

Risk Assessment: Of IINNW's 47 recent filings, 0 were flagged as high-risk, 33 as medium-risk, and 14 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.

Key Executives

• VP of Global Sales
• Board Member
• Joe Hayon
• Tal Parnes
• Benad Goldwasser

Top Tags

medical-device (12) · medical-devices (9) · press-release (6) · corporate-governance (5) · shareholder-meeting (4) · capital-raise (4) · medical-technology (3) · foreign-private-issuer (3) · offering (3) · healthcare (3)

Key Numbers

• Binding Purchase Orders: $49.5M — Reaffirmed value of existing orders, indicating sales traction.
• Financial Period: H1 2025 — Results reported cover the first half of 2025.
• Sensor Accuracy: 97.35% — Confirmed accuracy of the HYLA™ Real-Time Blood Sensor
• New Offering Price: $9.99M — Increased aggregate offering price of ordinary shares.
• Previous Offering Price: $7.12M — Original aggregate offering price of ordinary shares.
• HYLA Blood Sensor Accuracy: 97.35% — Indicates high performance in recent tests, moving towards FDA submission.
• Estimated Market Size: $20 billion — The potential market Inspira Technologies aims to lead with its ART500 technology.
• Purchase Order Value: $27 million — Secured from a government entity for ART100 systems.
• Gas Exchange Efficiency: 99% — Achieved in VORTX™ technology in-vivo animal testing
• Fiscal Year End: 2024 — The period covered by the annual report being amended.
• Filing Date: 20250328 — The date the amendment was submitted to the SEC.
• Minimum Bid Price: $1.00 — The threshold Inspira's stock price must maintain to remain listed on Nasdaq.
• Efficacy Rate: 95% — Achieved in preventing bloodstream infections
• U.S. Medical Device Spending: $199.1B — Represents market size in 2019, relevant to potential trade impacts.

Related Companies

INSP

Frequently Asked Questions